Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - What's Next?

Key Points

• Vaxart shares have fallen below their 200-day moving average of $0.42, currently trading at $0.39 with a trading volume of 802,784 shares.
• Institutional investors have shown significant interest, with Marshall Wace LLP and Jones Financial Companies among those increasing their stakes in Vaxart.
• The company is focused on developing oral recombinant protein vaccines, with several products in various stages of clinical trials, including norovirus and coronavirus vaccines.

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.42 and traded as low as $0.37. Vaxart shares last traded at $0.39, with a volume of 802,784 shares.

Vaxart Price Performance

The company's 50-day moving average is $0.38 and its 200-day moving average is $0.42. The firm has a market capitalization of $84.64 million, a price-to-earnings ratio of -1.37 and a beta of 1.33.

Hedge Funds Weigh In On Vaxart

Hedge funds and other institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its holdings in shares of Vaxart by 95.0% during the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after acquiring an additional 251,789 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Vaxart by 10.8% during the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 17,942 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Vaxart during the first quarter worth $56,000. Marshall Wace LLP acquired a new position in shares of Vaxart during the second quarter worth $794,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after purchasing an additional 478,111 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.